PBAC's latest decision on Anecortave acetate: Recommended with restriction (2006). Considered for treatment of subfoveal choroidal neovascularisation (CNV) due to exudative age related macular degeneration (AMD) where the CNV is composed predominantly (>50%) of classic lesions.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$200k/QALY
Range: $105k/QALY–$200k/QALY
Submissions
2
first 2006
Submissions
2
2006 → 2006
Eligible population
patients with predominantly (>50%) classic subfoveal choroidal neovascularisation (CNV) due to age related macular degeneration (AMD), as diagnosed by fluorescein angiography, and a baseline visual acuity equal to or better than 6/60 (20/200)
Therapy area
Ophthalmology
Evidence base
RCT
Key trials
C-01-99, C-98-03, C-00-07
Comparator
photodynamic therapy (PDT) with verteporfin
Economic model
CUA
Submission history
Mar 2006: Not recommended · Restricted
Nov 2006: Recommended with restriction · Authority Required — ICER $200k/QALY